ENTITY
BeiGene

BeiGene (6160 HK)

309
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
22 Jun 2020 16:03

Yum China HK Listing - Early Look - Relatively Bigger Deal Should Have a Relatively Bigger Impact

Yum China Holdings, Inc (YUMC US)  has filed confidentially for a secondary listing in Hong Kong, as per media reports. It aims to raise around...

Logo
452 Views
Share
bullishNetEase Inc
10 Jun 2020 11:24

NetEase Secondary Trading Update - Index Flows to Provide near Term Support

NetEase Inc (NTES US) raised US$3.1bn (including over-allocation) via its secondary listing in Hong Kong. I've covered various aspects of the deal...

Logo
457 Views
Share
08 Jun 2020 02:34

JD.com Secondary Listing: HK-ADS Premium/(Discount) Views

Hot on the heels of NetEase Inc (NTES US), JD.com Inc (ADR) (JD US) has launched a $4.3 billion secondary listing in Hong Kong. JD.com plans to...

Logo
400 Views
Share
bullishNetEase Inc
04 Jun 2020 12:13

NetEase Secondary Listing - Doing a BeiGene Rather than a Baba, Risk Reward Shifting

NetEase Inc (NTES US) ADRs have risen by 8% since its launched its secondary offering on 1st Jun 2020, which I covered in NetEase Secondary...

Logo
546 Views
Share
bullishNetEase Inc
02 Jun 2020 01:13

NetEase Secondary Listing: HK-ADS Premium/(Discount) Views

NetEase Inc (NTES US) has launched a $2.6 billion secondary listing in Hong Kong. This raise would be Hong Kong's biggest stock offering of the...

Logo
416 Views
Share
x